Advertisement

FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients

  • Katharina Dalus
  • Gundula Rendl
  • Lukas Rettenbacher
  • Christian Pirich
Letter to the Editor

Dear Sir,

The recently published study of Straver et al. describes the potential value of FDG PET/CT for monitoring neoadjuvant chemotherapy in a selective population of breast cancer patients.

Several annotations referring to both methodological and clinical aspects need to be made.

Straver et al. claim that a sufficiently prominent visualization of axillary lymph node metastases with FDG PET/CT allows monitoring of the axillary response. Several problems occurred in previous studies investigating the value of FDG PET(/CT) for monitoring response to neoadjuvant chemotherapy in breast cancer patients [1, 2, 3, 4]:

First, various criteria to define tumour response in breast cancer patients have been proposed: response can be assessed clinically and/or pathohistologically. Among the definitions of clinical response, the criteria validated by the Response Evaluation Criteria in Solid Tumours (RECIST) Group in the year 2000 is widely accepted and has been frequently used [5]. For...

Keywords

Breast Cancer Patient Axillary Lymph Node Standardize Uptake Value Axillary Lymph Node Metastasis Positive Axillary Lymph Node 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Berriolo-Riedinger A, Touzery C, Riedlinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34(12):1915–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36(10):1551–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24(34):5366–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009;27(4):535–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205–16.CrossRefPubMedGoogle Scholar
  6. 6.
    Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77(4):621–6.PubMedGoogle Scholar
  7. 7.
    Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4(2):125–31.PubMedGoogle Scholar
  8. 8.
    Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, et al. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 2009;16(12):3366–74.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Katharina Dalus
    • 1
  • Gundula Rendl
    • 1
  • Lukas Rettenbacher
    • 1
  • Christian Pirich
    • 1
  1. 1.Department of Nuclear Medicine and EndocrinologyParacelsus Private Medical University SalzburgSalzburgAustria

Personalised recommendations